Medicamen Biotech Ltd
Medicamen Biotech Ltd develops and markets a wide range of branded and generic formulations in the pharmaceutical industry.[1]
- Market Cap ₹ 486 Cr.
- Current Price ₹ 384
- High / Low ₹ 904 / 355
- Stock P/E 34.1
- Book Value ₹ 159
- Dividend Yield 0.26 %
- ROCE 10.6 %
- ROE 8.78 %
- Face Value ₹ 10.0
Pros
- Company is expected to give good quarter
Cons
- The company has delivered a poor sales growth of 4.34% over past five years.
- Company has a low return on equity of 9.63% over last 3 years.
- Dividend payout has been low at 8.80% of profits over last 3 years
- Company has high debtors of 159 days.
* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.
Peer comparison
Sector: Pharmaceuticals Industry: Pharmaceuticals - Indian - Formulations
Quarterly Results
Standalone Figures in Rs. Crores / View Consolidated
Profit & Loss
Standalone Figures in Rs. Crores / View Consolidated
Mar 2012 | Mar 2013 | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | TTM | |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|
101 | 64 | 73 | 78 | 67 | 82 | 112 | 123 | 117 | 110 | 115 | 138 | 165 | |
98 | 64 | 68 | 73 | 62 | 71 | 95 | 105 | 99 | 90 | 91 | 113 | 139 | |
Operating Profit | 3 | -0 | 5 | 5 | 6 | 12 | 17 | 17 | 18 | 20 | 24 | 25 | 26 |
OPM % | 3% | -0% | 7% | 6% | 8% | 14% | 15% | 14% | 15% | 18% | 21% | 18% | 16% |
1 | 1 | 1 | 1 | 1 | 0 | 2 | 4 | 2 | 1 | 2 | 2 | 2 | |
Interest | 3 | 4 | 4 | 4 | 4 | 4 | 3 | 1 | 1 | 2 | 2 | 3 | 3 |
Depreciation | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 3 | 6 | 6 | 7 |
Profit before tax | -1 | -5 | 0 | 0 | 1 | 6 | 14 | 18 | 17 | 17 | 18 | 17 | 18 |
Tax % | -28% | -1% | 44% | -267% | 32% | 19% | 27% | 31% | 26% | 25% | 18% | 13% | |
-1 | -5 | 0 | 0 | 0 | 5 | 10 | 12 | 12 | 12 | 15 | 15 | 14 | |
EPS in Rs | -1.01 | -5.81 | 0.10 | 0.46 | 0.48 | 4.91 | 8.89 | 10.28 | 10.04 | 10.22 | 12.20 | 11.86 | 11.26 |
Dividend Payout % | 0% | 0% | 0% | 0% | 0% | 0% | 12% | 10% | 5% | 10% | 8% | 8% |
Compounded Sales Growth | |
---|---|
10 Years: | 8% |
5 Years: | 4% |
3 Years: | 6% |
TTM: | 33% |
Compounded Profit Growth | |
---|---|
10 Years: | 18% |
5 Years: | 8% |
3 Years: | 7% |
TTM: | 4% |
Stock Price CAGR | |
---|---|
10 Years: | 42% |
5 Years: | -5% |
3 Years: | -10% |
1 Year: | -41% |
Return on Equity | |
---|---|
10 Years: | 11% |
5 Years: | 11% |
3 Years: | 10% |
Last Year: | 9% |
Balance Sheet
Standalone Figures in Rs. Crores / View Consolidated
Mar 2012 | Mar 2013 | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Sep 2023 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Equity Capital | 8 | 8 | 9 | 10 | 10 | 11 | 12 | 12 | 12 | 12 | 12 | 13 | 13 |
Reserves | 11 | 7 | 7 | 7 | 8 | 15 | 63 | 75 | 110 | 122 | 136 | 181 | 189 |
14 | 17 | 15 | 21 | 19 | 18 | 14 | 12 | 11 | 19 | 26 | 26 | 29 | |
35 | 33 | 33 | 31 | 23 | 30 | 28 | 38 | 43 | 39 | 52 | 57 | 66 | |
Total Liabilities | 69 | 65 | 65 | 69 | 60 | 73 | 118 | 137 | 176 | 192 | 226 | 277 | 296 |
23 | 23 | 22 | 20 | 19 | 19 | 25 | 24 | 34 | 90 | 92 | 92 | 92 | |
CWIP | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 15 | 40 | 0 | 0 | 0 | 0 |
Investments | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 2 | 2 | 2 | 4 | 6 |
46 | 42 | 42 | 49 | 41 | 54 | 92 | 97 | 100 | 101 | 131 | 180 | 198 | |
Total Assets | 69 | 65 | 65 | 69 | 60 | 73 | 118 | 137 | 176 | 192 | 226 | 277 | 296 |
Cash Flows
Standalone Figures in Rs. Crores / View Consolidated
Mar 2012 | Mar 2013 | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|
-3 | -2 | 5 | -3 | 6 | 4 | -5 | 4 | 12 | 13 | 5 | -4 | |
-1 | -1 | -1 | 0 | -1 | -2 | -8 | -15 | -39 | -18 | -8 | -8 | |
3 | 2 | -4 | 3 | -5 | -1 | 33 | -4 | 21 | 6 | 4 | 28 | |
Net Cash Flow | -2 | -1 | 1 | -0 | 0 | 0 | 20 | -14 | -6 | 1 | 1 | 17 |
Ratios
Standalone Figures in Rs. Crores / View Consolidated
Mar 2012 | Mar 2013 | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|
Debtor Days | 86 | 105 | 102 | 124 | 87 | 114 | 126 | 129 | 137 | 165 | 193 | 159 |
Inventory Days | 63 | 122 | 95 | 95 | 95 | 102 | 77 | 67 | 85 | 28 | 188 | 230 |
Days Payable | 158 | 225 | 209 | 187 | 160 | 165 | 118 | 134 | 160 | 161 | 291 | 232 |
Cash Conversion Cycle | -10 | 1 | -13 | 32 | 22 | 51 | 85 | 62 | 62 | 32 | 91 | 157 |
Working Capital Days | 29 | 50 | 44 | 80 | 83 | 96 | 135 | 151 | 162 | 166 | 207 | 213 |
ROCE % | 6% | -3% | 13% | 12% | 12% | 25% | 25% | 20% | 15% | 13% | 12% | 11% |
Documents
Announcements
- Announcement under Regulation 30 (LODR)-Trading Plan under SEBI (PIT) Regulations, 2015 2d
-
Announcement Under Regulation 30 Of SEBI (LODR) Regulations, 2015
2d - FDA has conducted audit of Oncology Plant, Haridwar. We are awaiting the plant approval from FDA. Meanwhile we have submitted dossiers for 10 oncology products …
-
Announcement under Regulation 30 (LODR)-Acquisition
23 Mar - Disclosure under Regulation 29(2) of SAST Regulations, 2011 received from Shivalik Rasayan Limited for purchase of 200000 Equity Shares from open market
-
Announcement under Regulation 30 (LODR)-Acquisition
23 Mar - Disclosure under regulation 29(2) of SAST Regulations, 2011 received from Growel Remedies Limited for sale of 200000 Equity Shares
-
Announcement under Regulation 30 (LODR)-Trading Plan under SEBI (PIT) Regulations, 2015
23 Mar - Form C pursuant to Regulation 7(2)(a) of PIT Regulations, 2015, received from Shivalik Rasayan Limited for purchase of 200000 Equity Shares from open market.
Annual reports
-
Financial Year 2023
from bse
-
Financial Year 2022
from bse
-
Financial Year 2021
from bse
-
Financial Year 2020
from bse
-
Financial Year 2019
from bse
-
Financial Year 2018
from bse
-
Financial Year 2017
from bse
-
Financial Year 2016
from bse
-
Financial Year 2015
from bse
-
Financial Year 2014
from bse
-
Financial Year 2013
from bse
-
Financial Year 2012
from bse
-
Financial Year 2011
from bse
-
Financial Year 2010
from bse
-
Financial Year 2009
from bse
Product Offerings
The Company manufactures formulations for anti-retroviral, oncology, cardiovascular, diabetic and hypertension, nutraceutical, and other products. Its key products are Efavirenz, Tenofovir (TDF), Gemcitabine, and Finished Dosage Forms (FDF) of these Products and Bio-Technology. [1]